This multi-part phase III trial of patients with treatment-naïve, stage IV or recurrent non-small-cell lung cancer (NSCLC) has previously shown a progression-free survival benefit with nivolumab plus ipilimumab versus chemotherapy in the subgroup with a high tumor mutational burden.
The final analysis of part 1 was presented at the ESMO Congress 2019 and demonstrated that nivolumab plus low-dose ipilimumab is a viable non-chemotherapy option for first-line treatment of advanced NSCLC.
Solange Peters discusses the implications of the CheckMate 227 findings and outlines the key next steps (3:45):